-
August 2, 2021
R&D Pipeline as of August 2021 -
August 2, 2021
The First Quarter of FY2021 (April 2021 - June 2021) -
May 11, 2021
Annual of FY2020 (April 2020 - March 2021) -
February 1, 2021
The Third Quarter of FY2020 (April 2020- December 2020) -
November 13, 2020
Annual Report 2020
-
August 5, 2021
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor Fostamatinib with Inmagene Biopharmaceuticals -
July 1, 2021
Phase III Clinical Study Data of AJM300 (Nonproprietary Name: Carotegrast Methyl) Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3 Study) will be presented in the 16th Congress of European Crohn's and Colitis Organisation (ECCO'21) -
June 28, 2021
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor "Fostamatinib (R788)" with JW Pharmaceutical Corporation -
June 23, 2021
Announcement of Marketing Authorization Approval in Japan and Co-promotion Agreement of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients -
May 28, 2021
EA Pharma Filed Marketing Approval Application for AJM300 (Nonproprietary Name: Carotegrast Methyl) Indicated for Treatment of Ulcerative Colitis
